Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer

被引：86

作者：

Song, Haa-Na ^{[1
,2
]}

Jung, Ki Sun ^{[1
]}

Yoo, Kwai Han ^{[1
]}

Cho, Jinhyun ^{[1
]}

Lee, Ji Yun ^{[1
]}

Lim, Sung Hee ^{[1
]}

Kim, Hae Su ^{[1
]}

Sun, Jong-Mu ^{[1
]}

Lee, Se-Hoon ^{[1
]}

Ahn, Jin Seok ^{[1
]}

Park, Keunchil ^{[1
]}

Choi, Yoon-La ^{[3
]}

Park, Woongyang ^{[4
,5
]}

Ahn, Myung-Ju ^{[1
]}

机构：

[1] Sungkyunkwan Univ, Div Hematol & Oncol, Samsung Med Ctr, Dept Med,Sch Med, Seoul, South Korea

[2] Gyeongsang Natl Univ, Dept Internal Med, Sch Med, Jinju, South Korea

[3] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Pathol, Seoul, South Korea

[4] Samsung Genome Inst, Seoul, South Korea

[5] Sungkyunkwan Univ, Sch Med, Dept Mol Cell Biol, Seoul, South Korea

来源：

JOURNAL OF THORACIC ONCOLOGY | 2016年 / 11卷 / 04期

关键词：

EGFR; T790M mutation; HM61713; C797S mutation;

D O I：

10.1016/j.jtho.2015.12.093

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

T790M mutation is most common resistant mechanism to epidermal growth factor receptor gene (EGFR) tyrosin kinase inhibitor (TKI). Several third-generation EGFR-mutant selective TKI, such as AZD9291 (AstraZeneca), Rociletinib (Clovis), or HM61713 (Hanmi) have been developed. Acquired resistant C797S mutation was known to be one of the resistance mechanisms of AZD9291, which has not been reported for HM61713 yet. This is the first case report of C797S mutation as resistance mechanism of HM61713. (C) 2015 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

引用

页码：E45 / E47

页数：5

共 5 条

[1]

[Anonymous], 2015, J CLIN ONCOL S

[2] Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models [J].

Eberlein, Catherine A. ;

Stetson, Daniel ;

Markovets, Aleksandra A. ;

Al-Kadhimi, Katherine J. ;

Lai, Zhongwu ;

Fisher, Paul R. ;

Meador, Catherine B. ;

Spitzler, Paula ;

Ichihara, Eiki ;

Ross, Sarah J. ;

Ahdesmaki, Miika J. ;

Ahmed, Ambar ;

Ratcliffe, Laura E. ;

O'Brien, Elizabeth L. Christey ;

Barnes, Claire H. ;

Brown, Henry ;

Smith, Paul D. ;

Dry, Jonathan R. ;

Beran, Garry ;

Thress, Kenneth S. ;

Dougherty, Brian ;

Pao, William ;

Cross, Darren A. E. .

CANCER RESEARCH, 2015, 75 (12) :2489-2500

[3] AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer [J].

Jaenne, Pasi A. ;

Yang, James Chih-Hsin ;

Kim, Dong-Wan ;

Planchard, David ;

Ohe, Yuichiro ;

Ramalingam, Suresh S. ;

Ahn, Myung-Ju ;

Kim, Sang-We ;

Su, Wu-Chou ;

Horn, Leora ;

Haggstrom, Daniel ;

Felip, Enriqueta ;

Kim, Joo-Hang ;

Frewer, Paul ;

Cantarini, Mireille ;

Brown, Kathryn H. ;

Dickinson, Paul A. ;

Ghiorghiu, Serban ;

Ranson, Malcolm .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (18) :1689-1699

[4] EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients [J].

Planchard, D. ;

Loriot, Y. ;

Andre, F. ;

Gobert, A. ;

Auger, N. ;

Lacroix, L. ;

Soria, J. C. .

ANNALS OF ONCOLOGY, 2015, 26 (10) :2073-2078

[5] Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain [J].

Yu, Helena A. ;

Tian, Shaozhou K. ;

Drilon, Alexander E. ;

Borsu, Laetitia ;

Riely, Gregory J. ;

Arcila, Maria E. ;

Ladanyi, Marc .

JAMA ONCOLOGY, 2015, 1 (07) :981-983

← 1 →